Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shVRK1 is an experimental short hairpin RNA (shRNA) construct designed to silence the expression of Vaccinia-related kinase 1 (VRK1). VRK1 is a serine/threonine protein kinase that plays a critical role in cell proliferation by regulating cell-cycle progression and mediating cellular responses to stress signals. Research indicates that VRK1 is highly expressed in small cell neuroendocrine carcinoma of the uterine cervix (SCNEC), particularly in cases with low expression of its paralog, VRK2. By knocking down VRK1, shVRK1 suppresses tumor growth and enhances sensitivity to oxidative stress, suggesting its potential as a therapeutic strategy for aggressive neuroendocrine cervical cancers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on shVRK1.